QR Kod

Phase II study of rucaparib and nivolumab in patients with leiomyosarcoma

Background Objective responses to immune checkpoint inhibitors (ICI) in leiomyosarcoma (LMS) are rare. Response rates may be increased by combination with other drugs known to promote immune infiltration, such as poly(ADP-ribose) polymerase (PARP) inhibitors, which have led to benefit in BRCA-altere...

Ful tanımlama

Kaydedildi:
Asıl Yazarlar: Robert G Maki, Martina Bradic, Phillip Wong, William Tap, Vicky Makker, Sandra D’Angelo, Angela Green, Mrinal M Gounder, Evan Rosenbaum, Ciara M Kelly, Jason E Chan, Ping Chi, Mark A Dickson, Mary L Keohan, Sujana Movva, Viswatej Avutu, Martee L Hensley, Maria M Rubinstein, Ronak Shah, Kenneth Seier, Karmelina Charalambous, Seth M Cohen, Lauren B Banks, Sara Saunds, Jae-Mun Cho, Robert A Lefkowitz, Joseph Erinjeri, Li-Xuan Qin
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: BMJ Publishing Group 2025-06-01
Seri Bilgileri:Journal for ImmunoTherapy of Cancer
Online Erişim:https://jitc.bmj.com/content/13/6/e012020.full
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller